Breast Cancer Research and Treatment

, Volume 131, Issue 3, pp 837–848

The chemokine receptor CCR4 promotes tumor growth and lung metastasis in breast cancer

  • Ji-Yu Li
  • Zhou-Luo Ou
  • San-Jian Yu
  • Xiao-Li Gu
  • Chen Yang
  • Ao-Xiang Chen
  • Gen-Hong Di
  • Zhen-Zhou Shen
  • Zhi-Ming Shao
Preclinical study

Abstract

Increasing evidence has shown that chemokines and chemokine receptors are associated with tumor growth and metastasis. CCR4, an important chemokine receptor for regulating immune homeostasis, is thought to be involved in hematologic malignancies and has also recently implicated in some solid tumors, such as gastric cancer. The possible role of CCR4 in breast cancer has not been well elucidated. In this study, we show that CCR4 is differentially expressed in human breast cancer cell lines. Specifically, we find that CCR4 is overexpressed in breast cancer cell lines with high metastatic potential. More importantly, we used a combination of overexpression and RNA interference to demonstrate that CCR4 promotes breast tumor growth and lung metastasis in mice. Furthermore, we find that microvessel density is significantly increased in tumors formed by CCR4-overexpressing cells and decreased in those formed by CCR4-knockdown cells. We find that overexpression of CCR4 can enhance the chemotactic response of breast cancer cells to CCL17. However, the expression of CCR4 does not affect the proliferation of breast cancer cells in vitro. Furthermore, we show that CCR4 expression is positively correlated with HER2 expression, tumor recurrence and lymph node, lung and bone metastasis (P < 0.05). Multivariate analysis showed that CCR4 expression is a significant independent prognostic factor for overall survival (P = 0.036) but not for disease-free survival in patients with breast cancer (P = 0.071). Survival analysis indicated a strong association between CCR4 expression and lower overall survival (P = 0.0001) and disease-free survival (P = 0.016) in breast cancer.

Keywords

Breast cancer Metastasis CCR4 Chemokine 

References

  1. 1.
    Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5):277–300PubMedCrossRefGoogle Scholar
  2. 2.
    Balkwill F (2003) Chemokine biology in cancer. Semin Immunol 15(1):49–55PubMedCrossRefGoogle Scholar
  3. 3.
    Ali S, Lazennec G (2007) Chemokines: novel targets for breast cancer metastasis. Cancer Metastasis Rev 26(3–4):401–420PubMedCrossRefGoogle Scholar
  4. 4.
    Baggiolini M (1998) Chemokines and leukocyte traffic. Nature 392(6676):565–568PubMedCrossRefGoogle Scholar
  5. 5.
    Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410(6824):50–56PubMedCrossRefGoogle Scholar
  6. 6.
    Manes S, Mira E, Colomer R, Montero S, Real LM, Gomez-Mouton C, Jimenez-Baranda S, Garzon A, Lacalle RA, Harshman K, Ruiz A, Martinez AC (2003) CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J Exp Med 198(9):1381–1389PubMedCrossRefGoogle Scholar
  7. 7.
    Miao Z, Luker KE, Summers BC, Berahovich R, Bhojani MS, Rehemtulla A, Kleer CG, Essner JJ, Nasevicius A, Luker GD, Howard MC, Schall TJ (2007) CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci USA 104(40):15735–15740PubMedCrossRefGoogle Scholar
  8. 8.
    Feng LY, Ou ZL, Wu FY, Shen ZZ, Shao ZM (2009) Involvement of a novel chemokine decoy receptor CCX-CKR in breast cancer growth, metastasis and patient survival. Clin Cancer Res 15(9):2962–2970PubMedCrossRefGoogle Scholar
  9. 9.
    Wang J, Ou ZL, Hou YF, Luo JM, Shen ZZ, Ding J, Shao ZM (2006) Enhanced expression of Duffy antigen receptor for chemokines by breast cancer cells attenuates growth and metastasis potential. Oncogene 25(54):7201–7211PubMedCrossRefGoogle Scholar
  10. 10.
    Wu FY, Ou ZL, Feng LY, Luo JM, Wang LP, Shen ZZ, Shao ZM (2008) Chemokine decoy receptor d6 plays a negative role in human breast cancer. Mol Cancer Res 6(8):1276–1288PubMedCrossRefGoogle Scholar
  11. 11.
    Zeng XH, Ou ZL, Yu KD, Feng LY, Yin WJ, Li J, Shen ZZ, Shao ZM (2011) Coexpression of atypical chemokine binders (ACBs) in breast cancer predicts better outcomes. Breast Cancer Res Treat 125(3):715–727PubMedCrossRefGoogle Scholar
  12. 12.
    Imai T, Nagira M, Takagi S, Kakizaki M, Nishimura M, Wang J, Gray PW, Matsushima K, Yoshie O (1999) Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int Immunol 11(1):81–88PubMedCrossRefGoogle Scholar
  13. 13.
    Ghia P, Strola G, Granziero L, Geuna M, Guida G, Sallusto F, Ruffing N, Montagna L, Piccoli P, Chilosi M, Caligaris-Cappio F (2002) Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+T cells by producing CCL22. Eur J Immunol 32(5):1403–1413PubMedCrossRefGoogle Scholar
  14. 14.
    Ishida T, Ueda R (2006) CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci 97(11):1139–1146PubMedCrossRefGoogle Scholar
  15. 15.
    Yoshie O, Fujisawa R, Nakayama T, Harasawa H, Tago H, Izawa D, Hieshima K, Tatsumi Y, Matsushima K, Hasegawa H, Kanamaru A, Kamihira S, Yamada Y (2002) Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood 99(5):1505–1511PubMedCrossRefGoogle Scholar
  16. 16.
    Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, Yamaguchi K, Yamada Y, Hanada S, Tamura K, Nakamura S, Inagaki H, Ohshima K, Kiyoi H, Ishida T, Matsushima K, Akinaga S, Ogura M, Tomonaga M, Ueda R (2010) Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 28(9):1591–1598PubMedCrossRefGoogle Scholar
  17. 17.
    Lee JH, Cho YS, Lee JY, Kook MC, Park JW, Nam BH, Bae JM (2009) The chemokine receptor CCR4 is expressed and associated with a poor prognosis in patients with gastric cancer. Ann Surg 249(6):933–941PubMedCrossRefGoogle Scholar
  18. 18.
    Olkhanud PB, Baatar D, Bodogai M, Hakim F, Gress R, Anderson RL, Deng J, Xu M, Briest S, Biragyn A (2009) Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. Cancer Res 69(14):5996–6004PubMedCrossRefGoogle Scholar
  19. 19.
    Li DQ, Wang L, Fei F, Hou YF, Luo JM, Zeng R, Wu J, Lu JS, Di GH, Ou ZL, Xia QC, Shen ZZ, Shao ZM (2006) Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatography-ion trap-mass spectrometry. Proteomics 6(11):3352–3368PubMedCrossRefGoogle Scholar
  20. 20.
    Burdette JE, Jeruss JS, Kurley SJ, Lee EJ, Woodruff TK (2005) Activin A mediates growth inhibition and cell cycle arrest through Smads in human breast cancer cells. Cancer Res 65(17):7968–7975PubMedGoogle Scholar
  21. 21.
    Luker GD, Pica CM, Kumar AS, Covey DF, Piwnica-Worms D (2000) Effects of cholesterol and enantiomeric cholesterol on P-glycoprotein localization and function in low-density membrane domains. Biochemistry 39(26):7651–7661PubMedCrossRefGoogle Scholar
  22. 22.
    Benelli R, Lorusso G, Albini A, Noonan DM (2006) Cytokines and chemokines as regulators of angiogenesis in health and disease. Curr Pharm Des 12(24):3101–3115PubMedCrossRefGoogle Scholar
  23. 23.
    Romagnani P, Lasagni L, Annunziato F, Serio M, Romagnani S (2004) CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol 25(4):201–209PubMedCrossRefGoogle Scholar
  24. 24.
    Kawakami K, Kawakami M, Snoy PJ, Husain SR, Puri RK (2001) In vivo overexpression of IL-13 receptor alpha2 chain inhibits tumorigenicity of human breast and pancreatic tumors in immunodeficient mice. J Exp Med 194(12):1743–1754PubMedCrossRefGoogle Scholar
  25. 25.
    Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29(6 Suppl 16):15–18PubMedGoogle Scholar
  26. 26.
    Zlotnik A, Yoshie O (2000) Chemokines: a new classification system and their role in immunity. Immunity 12(2):121–127PubMedCrossRefGoogle Scholar
  27. 27.
    Lo IC, Shih JM, Jiang MJ (2005) Reactive oxygen species and ERK 1/2 mediate monocyte chemotactic protein-1-stimulated smooth muscle cell migration. J Biomed Sci 12(2):377–388PubMedCrossRefGoogle Scholar
  28. 28.
    Barao I, Hanash AM, Hallett W, Welniak LA, Sun K, Redelman D, Blazar BR, Levy RB, Murphy WJ (2006) Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+ CD25+ regulatory T cells. Proc Natl Acad Sci USA 103(14):5460–5465PubMedCrossRefGoogle Scholar
  29. 29.
    Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, Zhou X, Xia W, Hortobagyi GN, Yu D, Hung MC (2004) Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 6(5):459–469PubMedCrossRefGoogle Scholar
  30. 30.
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  • Ji-Yu Li
    • 1
  • Zhou-Luo Ou
    • 1
  • San-Jian Yu
    • 1
  • Xiao-Li Gu
    • 1
  • Chen Yang
    • 1
  • Ao-Xiang Chen
    • 1
  • Gen-Hong Di
    • 1
  • Zhen-Zhou Shen
    • 1
  • Zhi-Ming Shao
    • 1
    • 2
  1. 1.Breast Cancer Institute, Cancer Hospital, Department of Oncology, Shanghai Medical College, Institutes of Biomedical ScienceFudan UniversityShanghaiChina
  2. 2.Department of Breast Surgery, Cancer Hospital/Cancer Institute, Breast Cancer InstituteFudan UniversityShanghaiChina

Personalised recommendations